This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Application of ATP Infusions in Palliative Home Care

This study has been completed.
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by:
Maastricht University Medical Center Identifier:
First received: November 28, 2007
Last updated: October 24, 2016
Last verified: November 2007
Palliative care in cancer aims at alleviating the suffering of patients. A previous study in patients with advanced non-small-cell lung cancer showed that adenosine 5'-triphosphate (ATP) infusions had a favourable effect on fatigue, appetite, body weight, muscle strength, functional status, quality of life, and survival. Based on these promising results, the present study was designed 1. To evaluate whether the beneficial effects of ATP administration observed in patients with advanced lung cancer would also be present in pre-terminal cancer patients of different tumour types, and 2. To test the feasibility of application of ATP infusions in a home care setting.

Condition Intervention Phase
Cancer Palliative Care Survival Quality of Life Drug: Adenosine 5'-triphosphate Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Application of Adenosine 5'-Triphosphate (ATP) Infusions in Palliative Home Care

Resource links provided by NLM:

Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:
  • Survival Physical restriction Fatigue Quality of life [ Time Frame: 0-8 weeks ]

Secondary Outcome Measures:
  • Appetite Nutritional intake Body height Body weight Triceps skin fold thickness Mid-upper arm circumference Strength of elbow flexor and knee extensor muscles Handgrip strength Process evaluation [ Time Frame: 0-8 weeks ]

Enrollment: 100
Study Start Date: March 2002
Study Completion Date: October 2006
Arms Assigned Interventions
Experimental: I Drug: Adenosine 5'-triphosphate
Weekly ATP infusions (in total 8 infusions) during 8 - 12 hours in a maximum dose of 50 mcg/kg.min
No Intervention: C


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • cytologically or histologically confirmed cancer
  • medical treatment options restricted to supportive care
  • a life expectancy < 6 months
  • World Health Organization (WHO) performance status 1 or 2
  • suffering from at least one of the following complaints: fatigue, weight loss > 5% over the last 6 months, or anorexia

Exclusion Criteria:

  • symptomatic angina pectoris
  • symptomatic heart failure
  • any form of atrioventricular (AV) block (assessed by electrocardiogram)
  • life expectancy < 4 weeks
  • concurrent palliative chemotherapy
  • cognitive dysfunction, and other diseases hampering adequate follow up
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00565188

Maxima Medical Center
Eindhoven, Netherlands, 5600 PD
Catharina Hospital Eindhoven
Eindhoven, Netherlands, 5602 ZA
Atrium MC
Heerlen, Netherlands, 6419 PC
Maastricht University Hospital
Maastricht, Netherlands, 6202 AZ
University Medical Center Utrecht
Utrecht, Netherlands, 3508 GA
Sponsors and Collaborators
Maastricht University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development
Principal Investigator: P.C. Dagnelie, PhD Maastricht University - Department of Epidemiology
  More Information

Publications: Identifier: NCT00565188     History of Changes
Other Study ID Numbers: MEC 01-092.3
ZonMW 1135.0010
Study First Received: November 28, 2007
Last Updated: October 24, 2016

Additional relevant MeSH terms:
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Vasodilator Agents
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on August 17, 2017